• linkedin
  • Increase Font
  • Sharebar

    Investigational BCG-refractory NMIBC Tx shows promise

    Intravesical recombinant adenovirus interferon alfa with Syn3 (rAd-IFNα/Syn3; Instiladrin) as treatment for high-grade non-muscle-invasive bladder cancer (NMIBC) patients who are unresponsive to bacillus Calmette-Guerin (BCG) demonstrated acceptable toxicity and a clinically meaningful durable response that has been maintained beyond 36 months in some patients when investigated in a phase II study.

    The abstract reporting on the results of the open-label, multicenter trial was published online in the Journal of Clinical Oncology (Aug. 23, 2017). The study randomized patients equally into two groups to receive intravesical rAd-IFNα/Syn3 1 × 1011 viral particles (vp)/mL or 3 × 1011 vp/mL. Patients judged to have been cancer free at follow-up visits conducted at months 3, 6, and 9 were retreated at months 4, 7, and 10.

    Results of the primary endpoint analysis showed that at 12 months, 14 (35%) of 40 treated patients were high-grade recurrence-free. The response rate was comparable in the two dose groups. In comparison, valrubicin (Valstar), the only treatment approved by the FDA for BCG-refractory disease, has been associated with a 12-month complete response rate of only 8% to 10%.

    No patients in the phase II study developed a Grade 4 or 5 adverse event or discontinued treatment because of a drug-related adverse event. There were 10 Grade 3 adverse events that were considered to be serious, but of these, only one episode of diarrhea and one episode of acute renal failure secondary to a urinary tract infection were judged related to the study drug, and both issues resolved with medical therapy.

    Urgency and frequency of micturition were the most common adverse events (40%), but they were generally minor, transient, and could be minimized by pretreatment with anticholinergics.

    Next: Dr. Dinney discusses findings

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll